Recruitment

Recruitment Status
Unknown status

Inclusion Criteria

Three regular menstrual cycles before the study(21-35 days per cycle with 3-7 day's bleeding period, without amenorrhea or irregular bleeding).
Signed informed consent prior to entry into the trial.
Healthy women,aged 20-35 years who wish to use a contraceptive.
...
Three regular menstrual cycles before the study(21-35 days per cycle with 3-7 day's bleeding period, without amenorrhea or irregular bleeding).
Signed informed consent prior to entry into the trial.
Healthy women,aged 20-35 years who wish to use a contraceptive.
Women without reproductive system infection complications.
Willingness to not use other forms of hormonal treatment.

Exclusion Criteria

Any contraindication to the use of oral contraceptives.
Vascular, metabolic, hepatic, renal, oncologic and other diseases.
Any contraindication to the use of oral contraceptives.
Vascular, metabolic, hepatic, renal, oncologic and other diseases.

Summary

Conditions
Oral Contraceptive
Type
Interventional
Phase
Phase 3
Design
  • Allocation: Randomized
  • Intervention Model: Parallel Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 20 years and 35 years
Gender
Only females

Inclusion Criteria

Three regular menstrual cycles before the study(21-35 days per cycle with 3-7 day's bleeding period, without amenorrhea or irregular bleeding).
Signed informed consent prior to entry into the trial.
Healthy women,aged 20-35 years who wish to use a contraceptive.
...
Three regular menstrual cycles before the study(21-35 days per cycle with 3-7 day's bleeding period, without amenorrhea or irregular bleeding).
Signed informed consent prior to entry into the trial.
Healthy women,aged 20-35 years who wish to use a contraceptive.
Women without reproductive system infection complications.
Willingness to not use other forms of hormonal treatment.

Exclusion Criteria

Any contraindication to the use of oral contraceptives.
Vascular, metabolic, hepatic, renal, oncologic and other diseases.
Any contraindication to the use of oral contraceptives.
Vascular, metabolic, hepatic, renal, oncologic and other diseases.

Tracking Information

NCT #
NCT02021097
Collaborators
Not Provided
Investigators
  • Principal Investigator: Chengliang Xiong, Dr Family Planning Research Institute of TJMC,HUST
  • Chengliang Xiong, Dr Family Planning Research Institute of TJMC,HUST